{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:23Z","timestamp":1792802123520,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17763"],"award-info":[{"award-number":["20K17763"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K07291"],"award-info":[{"award-number":["22K07291"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08986"],"award-info":[{"award-number":["22K08986"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15569"],"award-info":[{"award-number":["23K15569"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtho.2023.08.029","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:20:23Z","timestamp":1693682423000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion"],"prefix":"10.1016","volume":"19","author":[{"given":"Akira","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Oiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuta","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shimoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mitsudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.08.029_bib1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2023.08.029_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2023.08.029_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib4","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2023.08.029_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.08.029_bib6","article-title":"Molecular epidemiology and treatment patterns of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: the European EXOTIC registry","volume":"4","author":"Mountzios","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2023.08.029_bib7","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (TAK-788) in previously treated non\u2013small cell lung cancer with EGFR Exon 20 insertion mutations from a Phase I\/II trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.08.029_bib8","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.08.029_bib9","article-title":"Phase (Ph) 1\/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20)","volume":"40","author":"Yu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib10","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non\u2013small cell lung cancer with EGFR exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.08.029_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/1759-7714.13931","article-title":"Activity oftarloxotinib-Ein cells withEGFRexon-20 insertion mutations and mechanisms of acquired resistance","volume":"12","author":"Nishino","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2023.08.029_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-022-01299-z","article-title":"Foretinib can overcome common on-target resistance mutations after capmatinib\/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation","volume":"15","author":"Fujino","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in\u00a0vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib14","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an EGFR tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib15","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2009.26.7278","article-title":"Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors","volume":"28","author":"Yap","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4143\/crt.2017.303","article-title":"Phase 1 studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"50","author":"Kim","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jtho.2023.08.029_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non\u2013small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.08.029_bib19","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2021.10.014","article-title":"In\u00a0vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial","volume":"162","author":"Hamada","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.08.029_bib21","article-title":"Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations","volume":"2","author":"Vasconcelos","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2023.08.029_bib22","article-title":"EGFR-A763_Y764insFQEA is a unique Exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors","volume":"1","author":"Vasconcelos","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2023.08.029_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10555-012-9391-7","article-title":"Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny","volume":"31","author":"Suda","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jtho.2023.08.029_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/cells10020354","article-title":"Cell line models for acquired resistance to first-line osimertinib in lung cancers-applications and limitations","volume":"10","author":"Ohara","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jtho.2023.08.029_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.08.029_bib26","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.08.029_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/cas.15263","article-title":"Utility of the Ba\/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer","volume":"113","author":"Koga","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2023.08.029_bib29","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1021\/jm400072p","article-title":"Protein kinase inhibitor design by targeting the Asp\u2013Phe\u2013Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors","volume":"56","author":"Peng","year":"2013","journal-title":"J\u00a0Med Chem"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.08.029_bib30","article-title":"Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib","volume":"40","author":"Vincent","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.08.029_bib31","article-title":"The EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR Exon 20 insertion mutations","volume":"4","author":"Kagawa","year":"2023","journal-title":"JTO Clin Res Rep"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423007979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423007979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:49Z","timestamp":1761562369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423007979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1556086423007979"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.08.029","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}